Document Detail

Preliminary assessment of a 10-day rapid detoxification programme using high dosage buprenorphine.
MedLine Citation:
PMID:  9767204     Owner:  NLM     Status:  MEDLINE    
The original French therapeutic strategy for the treatment of opioid addiction was a rapid detoxification occasionally accompanied by treatment for withdrawal symptoms. In 1995, substitution therapy using opioids was introduced with the aim of maintenance, utilising methadone and the partial agonist buprenorphine, introduced in 1996. As well as being a maintenance agent, buprenorphine has been prescribed for rapid detoxification due to its reduced tendency to cause any withdrawal effects and its ability to block the effects of other opioids. This trial was initiated to measure the efficacy of buprenorphine in rapid detoxification and to assess whether additional medication would be required. Participants in this open study had requested rapid detoxification and were referred to the addiction clinic as inpatients. Patients were assessed by the clinician and during counselling sessions, and an initial dose was agreed upon. This dose was then gradually decreased over ten days in a flexible dosing schedule, with concurrent toxicological urinalysis to ensure no illicit drug use. During the trial, 25% of patients transferred to a maintenance programme and 58% remained in the study. The large transfer of patients to maintenance programmes may indicate that many people requesting rapid detoxification are actually asking for a more generalised form of assistance. No opioid-positive urines were noted after the fourth day in any patients, and the study indicates that buprenorphine should prove to be a useful detoxification agent, particularly in less hardened addicts. Step-down buprenorphine detoxification minimises withdrawal symptoms and, therefore, reduces the need for concurrent medication.
J Vignau
Related Documents :
25313684 - Use of non-steroidal anti-inflammatory drugs and risk of chronic kidney disease in peop...
11911374 - Duet-splitting and the evolution of gibbon songs.
14664324 - Pharmacology of drugs of abuse.
16323564 - The motivational component of withdrawal in opiate addiction: role of associative learn...
19113794 - Pharmacology and antifungal properties of anidulafungin, a new echinocandin.
11306214 - Violent traumatic events and drug abuse severity.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  European addiction research     Volume:  4 Suppl 1     ISSN:  1022-6877     ISO Abbreviation:  Eur Addict Res     Publication Date:  1998  
Date Detail:
Created Date:  1999-02-16     Completed Date:  1999-02-16     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9502920     Medline TA:  Eur Addict Res     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  29-31     Citation Subset:  IM    
Centre Hospitalier et Universitaire, Lille, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Buprenorphine / therapeutic use*
Dose-Response Relationship, Drug
Metabolic Detoxication, Drug
Narcotics / pharmacokinetics*,  therapeutic use*
Substance-Related Disorders / diagnosis*,  rehabilitation*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Narcotics; 52485-79-7/Buprenorphine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Differences between general practitioner- and addiction centre-prescribed buprenorphine substitution...
Next Document:  Buprenorphine maintenance in pregnant opiate addicts.